SCHEMBL25517581

SCHEMBL25517581

COCCOCc1ccc(C)cc1OCCOC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 8/20 0.44
MAPT P10636 7/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 6/20 0.44
HPGD P15428 3/20 0.44
MAPK1 P28482 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
USP2 O75604 1/20 0.44
POLB P06746 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX12 P18054 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 3/20 0.43
LMNA P02545 3/20 0.43
TDP1 Q9NUW8 2/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
PDE10A Q9Y233 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14915784 0.81 L3MBTL1 (0.45) L3MBTL1MAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL3152469 0.81 KDM4E (0.49) L3MBTL1MAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL13933168 0.81 L3MBTL1 (0.59) L3MBTL1MAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL19708262 0.81 L3MBTL1 (0.59) L3MBTL1MAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL10111041 0.79 TSHR (0.54) L3MBTL1MAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL18644135 0.79 TSHR (0.54) L3MBTL1MAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL12781859 0.78 L3MBTL1 (0.61) L3MBTL1MAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL29340937 0.78 ALDH1A1 (0.43) L3MBTL1MAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL13172532 0.78 IDO1 (0.37) ALDH1A1KDM4EPDE10A
SCHEMBL18074268 0.77 TAAR1 (0.48) L3MBTL1SMN1; SMN2ALDH1A1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 US disclosed
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF SSB, EBNA1BP2, PML L3MBTL1 2434/4885MAPT 2170/4885SMN1; SMN2 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.